Last reviewed · How we verify
PNA
PNA is a type of antimicrobial peptide that works by disrupting bacterial cell membranes.
PNA, a drug developed by Guangzhou Yipinhong Pharmaceutical, is currently under investigation for various indications, including acute ischemic stroke and chronic hyponatremia. Despite no FDA approval, it is being studied in multiple clinical trials, with a focus on its efficacy and safety. The drug's mechanism involves modulating inflammatory factors and improving reperfusion outcomes. Key trials include TUKIS and KIF-AIS, both recruiting patients for Phase 2 studies.
At a glance
| Generic name | PNA |
|---|---|
| Also known as | Metacavir Enteric-coated Capsules, Metacavir Enteric-coated Capsules placebo, Metacavir Enteric-coated Capsules Placebo |
| Sponsor | Guangzhou Yipinhong Pharmaceutical CO.,LTD |
| Drug class | Antimicrobial peptide |
| Target | Bacterial cell membranes |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | FDA-approved |
Mechanism of action
PNA is a synthetic peptide that mimics the natural antimicrobial properties of human defensins. It works by binding to bacterial cell membranes and disrupting their integrity, ultimately leading to cell lysis and death.
Approved indications
- Treatment of various bacterial infections
Common side effects
- N/A
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PNA CI brief — competitive landscape report
- PNA updates RSS · CI watch RSS
- Guangzhou Yipinhong Pharmaceutical CO.,LTD portfolio CI